They are also projecting the Low EPS estimate of $2.71 and the High EPS estimate of $2.8. The fund owned 13,385 shares of the pharmaceutical company's stock after selling 7,175 shares during the quarter.
Other analysts also recently issued reports about the stock. Zacks Investment Research raised shares of GlaxoSmithKline from a "hold" rating to a "buy" rating and set a $46.00 price target for the company in a research report on Wednesday, October 18th. Argus reduced their price target on GlaxoSmithKline to $40.00 and set a "buy" rating for the company in a report on Thursday, November 30th. Finally, Bryan, Garnier & Co reiterated a neutral rating and issued a GBX 1,710 ($23.19) price objective on shares of GlaxoSmithKline in a research report on Tuesday, September 19th.
When we look at the Analyst Recommendations of the stock, the company has 2.14 rating given by Analysts where 1 stands for Strong Buy and 5 stands for Strong Sell. GlaxoSmithKline has a consensus rating of "Hold" and a consensus price target of $38.57.
GlaxoSmithKline (GSK) traded up $0.03 during mid-day trading on Wednesday, hitting $38.20. The stock had a trading volume of 3,478,233 shares, compared to its average volume of 5,862,562. GlaxoSmithKline plc has a 1-year low of GBX 1,446.50 and a 1-year high of GBX 1,745.56. The stock has a market capitalization of $67,160.00 and a P/E ratio of 2,822.08.
Taking a quick look at technical levels and trend lines, we see that the stock has a 14-day ADX of 29.06.
GlaxoSmithKline (NYSE:GSK) last released its earnings results on Wednesday, October 25th.
The company's Average Earnings Estimate for the Current Fiscal quarter is $2.75, according to consensus of 5 analysts. GlaxoSmithKline had a net margin of 7.79% and a return on equity of 115.30%.
Large investors have recently bought and sold shares of the business. Finally, Comerica Securities Inc. boosted its position in shares of GlaxoSmithKline by 22.0% in the second quarter. King Luther Capital Management Corp grew its holdings in GlaxoSmithKline by 1.0% during the 2nd quarter. Company insiders own 10.00% of the company's stock. Catawba Capital Management VA's holdings in GlaxoSmithKline were worth $475,000 at the end of the most recent quarter. PagnatoKarp Partners LLC now owns 5,812 shares of the pharmaceutical company's stock valued at $253,000 after buying an additional 80 shares during the last quarter. Peapack Gladstone Financial Corp now owns 11,740 shares of the pharmaceutical company's stock worth $506,000 after acquiring an additional 115 shares during the last quarter. San Francisco Sentry Investment Group CA now owns 8,749 shares of the pharmaceutical company's stock worth $356,000 after purchasing an additional 4,589 shares during the period. Quadrant Capital Group LLC now owns 4,345 shares of the pharmaceutical company's stock worth $162,000 after acquiring an additional 148 shares during the last quarter.
In other GlaxoSmithKline news, major shareholder Plc Glaxosmithkline bought 428,571 shares of GlaxoSmithKline stock in a transaction dated Monday, November 6th. The shares were purchased at an average cost of $14.00 per share, for a total transaction of $5,999,994.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
The business also recently declared a quarterly dividend, which was paid on Thursday, January 11th. Investors of record on Friday, November 10th were given a $0.5037 dividend. This represents a $2.01 annualized dividend and a yield of 5.28%. This is a boost from GlaxoSmithKline's previous quarterly dividend of $0.49. The ex-dividend date is Thursday, August 10th. Currently, Capita Plc (CPI.L) has a 14-day ATR of 16.70.
COPYRIGHT VIOLATION WARNING: "Liberum Capital Reaffirms Buy Rating for GlaxoSmithKline (GSK)" was originally posted by Registrar Journal and is the sole property of of Registrar Journal. If you are accessing this piece on another website, it was illegally copied and reposted in violation of USA and global trademark and copyright laws.
Glaxosmithkline Plc (GSK) now has a 14-day Commodity Channel Index (CCI) of 107.60.